What is ChromaCode?
ChromaCode is at the forefront of providing advanced genomic solutions through its proprietary HDPCR multiplexing technology. The company's platform is designed to simplify complex data analysis, enabling faster and more cost-effective access to critical biomarkers. This is particularly impactful in oncology and genomics, where rapid and accurate molecular profiling is essential for improved patient care. ChromaCode's offerings support enhanced turnaround times and higher margins for laboratory partners, presenting a compelling alternative to conventional methods. The company's mission is to elevate health outcomes by developing customizable assays for diverse applications, including tumor profiling and disease monitoring.
How much funding has ChromaCode raised?
ChromaCode has raised a total of $50M across 2 funding rounds:
Series B
$12M
Series C
$38M
Series B (2017): $12M with participation from Domain Associates and New Enterprise Associates
Series C (2020): $38M led by Windham Ventures, Domain Associates, Adjuvant Capital, Northpond Ventures, Moore Venture Partners, California Institute of Technology, Okapi Venture Capital, and New Enterprise Associates
Key Investors in ChromaCode
Windham Ventures
Windham Ventures is an investment firm that likely focuses on strategic capital allocation within the venture landscape, potentially targeting companies with disruptive technologies.
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments. It manages nine subsequent biotech venture capital funds and has a total of $2.8 billion in assets. The firm has provided VC funding to 194 biopharmaceutical, device, and diagnostic companies, resulting in 90 IPOs and 110 M&A events, with a combined market cap of $190 billion for the funded companies. Its intended clients include biotech startups and investors looking to enter the biotech sector.
Adjuvant Capital
Adjuvant Capital is likely a venture capital firm that provides growth capital and strategic support to companies in the life sciences and healthcare sectors.
What's next for ChromaCode?
With the recent influx of enterprise-level capital, ChromaCode is poised for accelerated growth and market expansion. The company's focus on simplifying genomic data analysis and providing rapid biomarker identification suggests a strategic push towards broader clinical adoption. Future developments are likely to center on scaling its technology platform, forging new partnerships within the healthcare ecosystem, and potentially expanding its assay portfolio to address a wider range of diseases. The sustained investment indicates strong confidence in ChromaCode's ability to disrupt traditional diagnostic workflows and enhance personalized medicine.
See full ChromaCode company page
